Materiality pending
Public signal · 1-minute delayed
Signal brief
Source-backed market context you can read and share without an account.
AI summary
What happened, with direct paths to the underlying reporting
IMNN shares surged 168.5% on strong trial data for IMNN-001. Phase 2 trial showed 11.1 month increase in overall survival vs. standard care. 3-month improvement in progression-free survival signifies potential market impact. Company faces financial difficulties, with substantial operating losses and no revenue. Market capitalization stands at $30.3 million with significant trading volume spike.
- IMNN shares surged 168.5% on strong trial data for IMNN-001.
- Phase 2 trial showed 11.1 month increase in overall survival vs. standard care.
- 3-month improvement in progression-free survival signifies potential market impact.
- Company faces financial difficulties, with substantial operating losses and no revenue.
- Market capitalization stands at $30.3 million with significant trading volume spike.
How to read this signal
Transparent limits for an AI-generated research aid
StockNews.AI groups source reporting, classifies the event, and measures subsequent price movement. This is informational research, not investment advice. Prices may be delayed or unavailable.